chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Within a couple of hours from vaccine my arm started hurting, like muscular pain, and by night it turned into shooting red hot nerve pain down my arm. I couldn't lift or move my arm and I thought maybe it was just the shot. I took Advil and Tylenol and it didn't do anything. I couldn't sleep, pick up things, and I wound up going to urgent care because I didn't want to go to ER. They couldn't lift my arm without giving me horrible pain, and they gave me a low-dose steroid shot and told me there was nothing they could do and if it didn't work go to the ER. It didn't work so I sent my PCP a message and they sent me a prescription for higher dose steroid and I had to try and drive myself to the pharmacy which wasn't pretty, and I started the higher dose steroid. I had no use for my arm for 4-5 days and one of the medical people I spoke to thinks that it was a reaction to the vaccine and that the nurse hit the bursa in shoulder instead of more muscular so it affected the nerve in my arm. I did fine with the first vaccine, but this was just severe pain and I've had cancer and have had a shot called Neulasta that makes your bones feel like they're on fire and this was 20 times worse than that. It eventually went away after 5 days. The urgent care did no medical tests. I also had Omicron in Feburuary 2022 with symptoms including a blinding headache that made me feel like passing out, fever, and achiness. My home test lit up like a pregnancy test, and for the next 4-5 days I laid on the couch in the dark. I didn't lose taste or anything.
No known adverse events. Pt received the Novartis brand of influenza vaccine & Novartis vaccine is recommended for children 4 yrs of age & older.
Body aches 2 weeks after 2nd shot; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Body aches 2 weeks after 2nd shot) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MYALGIA (Body aches 2 weeks after 2nd shot). At the time of the report, MYALGIA (Body aches 2 weeks after 2nd shot) outcome was unknown.            No concomitant medication were reported. No treatment information was reported.
Patient was vaccinated with Pfizer vaccine after previously completing the J&J vaccine.  J&J vaccination was completed on 03/10/21 and Pfizer first dose was administered on 08/08/21.  The patient experienced no adverse reaction.  He came back for 2nd dose of pfizer 21 days later when we found the error.
Widespread muscle spasms, pain and weakness over about 1/2 hour. I had a similar, yet more severe reaction to chemo and neulasta.
9/4/12 pm body aches, fever, severe stomach cramps and nausea 9/5/12 AM & continued.
This spontaneous report as received from a physician via Center regarding a baby unknown age and gender. The patient's relevant medical and drug histories and concomitant medications were unknown. On an unknown date, the office staff inadvertently administered an expired M-M-R II to the patient (indication, strength, dose, frequency, route, lot number and expiry date were unknown) (expired product administered). The physician reported that the baby was okay. Relevant lab data was unknown. As of 04-MAY-2018, it was unknown if the patient will be revaccinated with M-M-R II. This is one of the three reports linked via same reporter link. Sender's Comments: US-009507513-1805USA002977; US-009507513-1805USA002757.
Fever of 100.6, swollen left arm, red patch on left arm, injection spot red raised bump, fatigue.
This initial case was received from a healthcare professional on 10 February 2012. It represents a cluster of 10 unidentified patients reported by the same reporter who each experienced painful large welts at injections site following administration of FLUZONE INTRADERMAL. A group of 10 unidentified patients received an intradermal injection of FLUZONE INTRADERMAL, sanofi pasteur Inc. (lot numbers, routes, sites and dates of administration were not reported.) One of the patients, an office nurse, now has a "scar" at injection site. The patients' medical histories, concomitant medications, prior doses of vaccine, and vaccinations within four weeks prior to vaccine were not reported. The patients' outcomes were not reported. Documents held by sender: none.
Patient received vaccine in the L deltoid on 08/18/20 in office. Patient states that she reported redness, swelling, and pain below injection site (x1 inch below) about x1 hour after receiving injection. Pt. return to the office and was seen by provider on 08/20/20 reporting the incident. Patient denies having any reactions to immunizations before. Provider (FNP) diagnosed pt. with a allergic reaction to the immunization and prescribed a Prednisone 20MG for x5 days, pt. received a steroid injection at time of OV on 08/20/20 and was prescribed a antibiotic (Cephalexin) if symptoms worsen  or not improved after x2 day for pt. to take to prevent possible cellulitis.
Pt experienced pain, inflammation, erythema, and itching on and around injection site beginning the day after imz administration. Pt came to the pharmacy 1/5/16 and pt was advised to apply ice compress, take Benadryl, and acetaminophen, per protocol. Pt did not follow RPh advice and returned to pharmacy 1/6/16 with same issue.  Pt was advised to go to ERfor further examination.
Client received a booster dose of Pfizer (lot # FF2587 exp 10/30/21) at 1:35 PM in right deltoid. PHN'S were notified by EMT at 1:55 PM that client reported numbness in her mouth. PHN's reported to observation area immediately. Client is found with a red flushed face sitting in gravity chair. Client stated that her mouth feels sticky. Client denies shortness of breath, swelling in the throat and tongue, dizziness, headache, and itching. Client states that her vision is slightly blurry at her baseline and has not changed. Client states that she does not have allergies, has a history of cancer, and takes baby aspirin daily. Vital signs were taken at 1:55 PM (Blood Pressure 138/85, Heart Rate 79, and Oxygen saturation 97%). Client encouraged to drink water that was provided by EMT prior to PHNs arriving at scene. Fan and cool pack provided to client. At 2:00 PM, vital signs were taken again. Blood pressure was 151/98, heart rate was 74, and oxygen saturation was 98%. IM Benadryl was offered to client, but client refused medical intervention at this time. Client states she is driving herself and her husband home from vaccine site. Client stated that she lives one mile away. Client further states that that she had also experienced numbness in her mouth after her first dose of Pfizer. Client stated that the numbness resolved immediately, but that staff was aware of numbness. According to client, she did not have numbness after her second dose of Pfizer. At 2:02 PM, client?s face appears less flushed, and client states that she feels, ?less stickiness and less hot in face.? Client continued to use cool pack and at 2:07 PM, client states, ?I am starting to feel a lot better and am less warm than before.? Vital signs were taken, and blood pressure was 138/86, pulse was 71, and oxygen saturation was at 98%. Within ten minutes, client states, I only feel stickiness slightly in my mouth now.? Another set of vital signs were taken at this time and blood pressure was at 138/82, pulse was 70, and oxygen saturation was 99%. At this time, client is educated on ER precautions and was advised to follow up with her primary care provider within 24 hours. A final set of vital signs was taken at 2:25 PM, and blood pressure was 138/86, pulse was 72, and oxygen saturation was at 98%.
Information has been received from a patient's relative, referring to a 82 year old female patient. The patient's medical history and concurrent conditions were not reported. Concomitant therapies included unspecified pain medicines. It was reported, that 35 to 40 years ago the patient had the first round of unspecified shingles vaccine (in approximately 1977). On 03-JUN-2009, the patient was vaccinated with a dose of ZOSTAVAX (strength, dose, lot number, expiration date, anatomical location and administration route were not reported) for prophylaxis. On January 2017 (reported as "now in 2017"), the patient experienced a case of shingles (herpes zoster) and a vaccination failure (reported as "I wanted to submit a report for an ineffective vaccination"). The reporter's grandmother also mentioned that she was aware of another person who was vaccinated and still broke out with shingles (MARRS # 1701USA010282). The outcome of the events was not reported. The causality between the vaccination with ZOSTAVAX and the events was unknown. No product quality complaint (PQC) was involved. This is one of several reports received from the same source. Additional information has been requested.; Sender's Comments: US-009507513-1701USA010282:
Information has been received from a physician concerning an approximately 4 month old patient with no pertinent medical history who was vaccinated PO with the first dose of Rotateq. Concomitant vaccination administered within the same visit included a dose of MMR II. In September 2007, the patient developed bloody stools, vomiting and diarrhea. Unspecified medical attention was sought. It was noted that the patient "did not have any pain in the abdominal region." Subsequently, the patient was taken to a hospital. The patient was not recovered at the time of this report. There was no product quality complaint. Additional information has been requested.
Premature live birth 29 weeks; Maternal exposure during pregnancy first  trimester; This is a spontaneous report from a nurse (mother).   This other hcp reported information for both mother and fetus/baby.  This is a fetus/baby report.  A female patient of an unspecified age received bnt162b2 (BNT162B2), dose 2 transplacental on 24Jan2021 (Batch/Lot number EL3247) and  dose 1 transplacental on 03Jan2021 (Batch/Lot EK9231) both as single dose  for covid-19 immunisation  .  The patient medical history was not reported. Concomitant medications included multivitamins [vitamins nos] (MULTIVITAMINS [VITAMINS NOS]) taken for prenatal care from 01Dec2020 to 01Aug2021; folic acid (FOLATE) taken for prenatal care from 01Dec2020 to 01Aug2021; acetaminophen (ACETAMINOPHEN) taken for pain, start and stop date were not reported; multivitamins (MULTIVITAMINS [VITAMINS NOS]) taken for prenatal care from an unspecified start date and ongoing.  The patient experienced maternal exposure during pregnancy first  trimester  (hospitalization, medically significant) on 03Jan2021 with outcome of unknown , premature live birth 29 weeks  (hospitalization, medically significant) on 03Jun2021 with outcome of unknown.    The mother LMP was on 12Nov2020 and received the first dose of BNT162B2 on 03Jan2021 and the second dose on 24Jan2021. The mother delivered the baby via cesarean sectio. The baby weight at birth was 1200gr; and the APGAR score was 5 at the first minute and 8 at five minutes; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of events Maternal exposure during pregnancy, first trimester and Premature birth  cannot be totally excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
One day post vax, the pt't arm began swelling, to th axilla, was hot to the touch, red with small hives No  fever was given noted. The pt also experienced malaise. The pt is beginning to recover. No diarrhea nor a fever.
Vaccine received 11am, side effects occurred midnight that evening --chills (very strong, uncontrollable shivering) for several minutes, followed by fever. Elevated body temperature overnight, better the following morning. Tylenol effectively controlled fever
backache; congested; headache; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (backache), NASAL CONGESTION (congested) and HEADACHE (headache) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BACK PAIN (backache), NASAL CONGESTION (congested) and HEADACHE (headache). At the time of the report, BACK PAIN (backache), NASAL CONGESTION (congested) and HEADACHE (headache) outcome was unknown.            Congested is reported as an event. No concomitant medication was reported. No treatment information was provided.   Reporter did not allow further contact
Moderna COVID-19 Vaccine EUA Rash similar to eczema ; itching raised bright pink spots on left thigh and left elbow.  Applying moisturizer to area 2x/day.   Todays is day number 6, itchiness has subsided a bit.
This spontaneous report as received from a nurse refers to a 16 year old female patient. The patient had no pertinent medical history or drug reactions/allergies. In 1998 the patient was vaccinated with the first dose of (Oka/Merck) VARIVAX, lot# not reported, 0.5 nl, subcutaneously (indication reported as vaccination). In 2008 the patient was vaccinated with the second dose of (Oka/Merck) VARIVAX, lot# not reported, 0.5 ml, subcutaneously. No concomitant medications were reported. The nurse reported that patient developed a "significant localized reaction" after administration of (Oka/Merck) VARIVAX on an unspecified date. The nurse did not know if the reaction was after administration of the first or second dose of (Oka/Merck) VARIVAX. The reaction resolved without requiring treatment. The nurse added that the patient was administered the two doses of (Oka/Merck) VARIVAX and subsequently had negative antibody titers to varicella on 09-JUL-2014. No treatment was given for the adverse events. The patient had sought medical attention by office visit. At the time of the reporting, outcome of "negative antibody titers to varicella" was not recovered. The outcome of localized reaction was unknown. Additional information is not expected.
Two months post final dose left arm became entirely numb; extremely ill; bad cold four days after the injection; This is a spontaneous report from a contactable healthcare professional, the patient. A 29-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3246), via an unspecified route of administration in the left arm on 16Jan2021(at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history of the patient included common variable immune deficiency. The patient was allergic to sulfa. The patient received other medications (unspecified) within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EK9231), via an unspecified route of administration in the left arm on 26Dec2020 (at the age of 29-years-old) as a single dose for COVID-19 immunisation and experienced injection soreness on an unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Jan2021, the patient experienced the extreme illness and bad cold (four days after the injection). On 23Mar2021, 2 months after the second dose, the patient experienced the event entire left arm numbness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events illness, cold and numbness was unknown.   No follow-up attempts are needed. No further information is expected.
Tested positive for Covid-19 on 8/12/2021 after being exposed on 8/8/2021 Symptoms of sinus congestion/pressure, ear pain, sore throat started evening of 8/11/2021 monoclonal antibody infusion on 8/17/2021
Lymphadenopathy was bad Neck was really swollen lasted two weeks. Neck and lymph nodes were swollen Lymph nodes in the groin were so sore I couldn't walk. I got the Shingles about two weeks after the first dose .
4 hrs after injection to Lt lateral thigh, mother noticed a red dime size swelling lateral to the injection site. That evening the inject site had a palmed size red rash, hard swelling. By exam date 6/7/12 site was 2x2 with soft, hot head.
Large pericardial effusion diagnosed on 1/10 by transesophageal echocardiogram
This spontaneous case, initially received on 02-Nov-2016, was reported by a health professional and concerns a 47 year old patient. Weight: not provided; Height: not provided. Concomitant medication: Not reported. Administration of company suspect drug(s): On 16-Sep-2016 the patient received AFLURIA. Dose regimen: Not reported, Route of administration: Intramuscular. Batch number: WT54306. No additional suspect drugs. Adverse event description: On 23-Sep-2016, a nurse reported that a refrigerator went in or out of (temperature) range while there was flu vaccine in it. On 16-Sep-2016, doses were administered (special circumstances: drug administration error without adverse event, incorrect product storage without adverse event). Flu vaccine was first delivered to the vaccination facility on 15-Aug-2016. As the nurse reviewed the refrigerator temperature log, she stated that another excursion occurred on 15-Sep-2016. The doses arrived at 09:00 and were placed in a refrigerator that was at 10 degrees Celsius in the morning. Then the temperature remained at 9 degrees Celsius throughout the 15th and 51 doses were administered on the 16th at a flu clinic. The refrigerator was not back in range until 19-Sep-2016 at a temperature of 8 degrees Celsius. Temperature excursion identified: Log documentation reflected temperature excursions from 31-May-2016 and 23-Sep-2016 which ranged between 8 to 10 degrees Celsius. Vaccines had been given to patients between 31-May-2016 and 23-Sep-2016. On 04-Oct-2016, the remaining 42 doses of lot number WT54306 were discarded. The patients will be contacted for revaccination.
Immediately after vaccination - tachycardia, 12-14 hours after- rash and swollen eyes that increasingly worsened with time
Reaction to Moderna vaccine  #2 April 10, 2021. I had no reaction to #1 on March 11, 2021 11:00 a.m. I received my vaccine. I felt fine until about 4:00 p.m. 4:00 p.m. my arm was stiff and sore even though I had been massaging it and using it.  I also was getting sleepy. I had a dull headache in my rt. Eye socket area. 8:30 p.m.  my arm was very sore.  10:30 p.m. I fell asleep.  11:30 p.m. I woke up and felt feverish; I was hot but had chills, my body ached, my headache had worsened and spread to a larger area of my head, my skin hurt. 12:30 a.m. my reaction remained the same but more intense. This lasted until about 6:00 a.m. where it seemed to lessen. 10:00a.m. I was less achy and no chills. I still had a headache
Dry cough; Inflamation at the site of injection; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Dry cough) and VACCINATION SITE OEDEMA (Inflamation at the site of injection) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 ml. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Apr-2021, the patient experienced COUGH (Dry cough) and VACCINATION SITE OEDEMA (Inflamation at the site of injection). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 13-Apr-2021, VACCINATION SITE OEDEMA (Inflamation at the site of injection) had resolved. On 15-Apr-2021, COUGH (Dry cough) had resolved. Not Provided
approx 15 mins p/vax pt acting strange, coughing cont; p140, R34-40; pt scratching ears, eyelids puffing, skin red; wheezing;
Hands and feet broke out in blisters, blisters burst and now feet and hands raw.... no fever, chills..
MODERNA COVID VACCINE #3 GIVEN 10/26/21, LOT # 012F21A; 5/9/10 pt brought to ED via EMS with generalized weakness, SOB; found to be hypoxic and had a positive COVID test (although throughout hospital course, pt's COVID tests were all negative after the initial; possible false positive test); given O2, dexamethasone, admitted; worsening right pleural effusion and ascites; right chest tube placed with some improvement; decline later in status; family decided on comfort measures only and pt was put into hospice where he expired.
Severe pain in shoulder, unable to move arm. Continued through day and into night, when I noticed a swelling at injection sight. On 10/29/2016 at 6:00 am I woke with mild fever, continued swelling and heat at injection site, took ibuprofen and went on a hike. The fever spiked mid day and I went home and slept. 10/30/2016 fever down and pain subsided. Arm swelling and tenderness also decreased.
Felt like I was getting the flu. I had taken the flu shot at the same time since I was going overseas. Also experienced lethargy and fever. Broke out in a sweat and large flat blisters appeared on my right arm, the arm in which the shot was given. No swelling at injection site. After blisters appeared, the reaction stopped. All of this happened over a 24-hour period.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age with headaches, muscle spasms and blood pressure. On 12-MAR-2013 the patient was vaccinated with ZOSTAVAX vial 19400 PFU (lot # and expiration date unspecified) (dose, route and anatomical location unspecified). Concomitant medications included unspecified medications for headaches, muscle spasms and blood pressure. On 13-MAR-2013, the patient developed an itchy area "the size of a lemon" at the injection site after ZOSTAVAX was administered. At the time of the report the outcome of itchy area at the injection site was reported as not recovered/not resolved. The patient sought medial attention. There was not treatment given or laboratory tests performed. Additional information is not expected.
Patient started to experience increased heart rate, tingling of the tongue (possibly swelling) patient just said it felt weird, feeling flushed or feeling hot, back of neck seemed warm. Shot was given 12pm (noon) 15 minutes later patient started to experience these symptoms. Blood pressure was checked  initially (147/78).
24 hours after immunization - patient felt hot and dizzy - injection site red - warm to touch - much of arm and shoulder - was red - blood pressure OK and temperature OK - patient was improving 6/28/13.
Patient fainted within 5 minutes following vaccination. Was unconscious briefly. Upon awakening he was pale and nautious. Was provided a chair to sit, water, and juice.